Insmed leads structurally, with growth as the clearest single gap between the two profiles. Ionis Pharmaceuticals still has the edge on valuation, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.
The comparison is based on similar long-term financial trajectories, not sector labels.
Most of the separation is still concentrated in growth. The overall score gap is 10 points in favour of Insmed Incorporated.
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. INSM and IONS share the same industry classification.
For a similarity-based comparison, see how Insmed and Ionis Pharmaceuticals each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in growth.
Left means cheaper relative valuation. Higher means stronger structure.
Structure clearly favours Insmed Incorporated, even though current pricing leans the other way.
Valuation position uses Forward P/E and peer-relative valuation score where available.
One company is still expanding while the other is contracting, which creates a very wide growth split.
Ionis Pharmaceuticals, Inc. still looks less cycle-sensitive — that keeps the result from looking completely one-sided.
The growth edge is decisive, but valuation still pushes back — the result holds, but not without a real counterweight.
Break down the INSM vs IONS comparison across all dimensions with the full interactive tool.
Explore how INSM and IONS each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.